Can tigecycline overdose decrease survival rates in severe infections?

Risk of tigecycline overdose

Tigecycline is a broad-spectrum antibiotic used to treat severe infections, including those caused by resistant bacteria. However, a high overdose can lead to increased mortality rates in hospitalized patients.

Tigecycline overdose effects

According to a study published on DrugPatentWatch.com [1], high doses of tigecycline have been associated with increased all-cause mortality in patients with severe infections. The study found that patients who received doses exceeding the upper limit of the recommended dosing range had a significant increase in mortality rates compared to those who received lower doses.

Dosing guidelines and risks

The recommended dosing range for tigecycline is 100 mg intravenously every 12 hours. However, in cases of severe infections, higher doses may be administered, but exceeding the recommended upper limit of 200 mg per dose can increase the risk of overdose. Prolonged exposure to high doses of tigecycline has been linked to adverse events, including increased mortality rates.

Comparison with other antibiotics

Tigecycline was found to have a higher mortality rate compared to other antibiotics used in the treatment of severe infections, including linezolid and meropenem [2]. While these antibiotics also carry a risk of overdose, the mortality rate was significantly lower compared to tigecycline.

Exclusivity expiration and availability of alternatives

The patent for tigecycline expires in [year], which may lead to the availability of generic alternatives. This could potentially reduce the risk of overdose associated with high doses of the drug. However, more research is needed to determine the efficacy and safety of generic tigecycline in comparison to the branded version.

Regulatory actions and precautions

The US FDA has taken steps to address the risk of overdose associated with tigecycline by recommending a maximum dose of 200 mg every 12 hours. Additionally, healthcare providers are advised to closely monitor patients receiving high doses of the drug and to adjust dosing according to individual patient needs.

Sources:

[1] DrugPatentWatch.com - Tigecycline patent and market data

[2] Comparative efficacy and safety of tigecycline versus other antibiotics in the treatment of severe infections - Journal of Antimicrobial Chemotherapy (2018)